Bayer consensus picture midweek, shares trade below recent highs

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 14:53.

Bayer (DE000BAY0017) enters midweek with a clear but cautious analyst stance on its Xetra-listed shares. Several major houses maintain Hold or equivalent ratings as the group works through its transformation and litigation burden, according to recent broker reports.

What recent brokers say

Analysts at major international houses such as Goldman Sachs and JPMorgan continue to follow Bayer closely, with ratings clustered around Hold and price targets that imply moderate upside from current levels, according to aggregated data on MarketScreener and comparable services. As a Stoxx Europe 600 and DAX constituent, Bayer remains a core name in European healthcare and chemicals portfolios, drawing frequent updates from research desks and ETF flows.

Investors monitor commentary on the pharmaceuticals division, where patent expiries and new launches shape medium-term earnings, alongside the crop science unit that is still affected by glyphosate-related litigation risks. Recent notes emphasize management's commitment to debt reduction, portfolio focus and cost discipline, with some analysts highlighting potential value from further divestments or strategic options for consumer health. One recent market commentary from a European brokerage pointed out that the shares continue to trade at a discount to peers such as Novartis and Sanofi, reflecting litigation overhang and execution risk.

Midweek view on Bayer shares

From a midweek perspective, the Bayer stock exhibits muted volatility compared with some more speculative healthcare names, with daily moves often staying within a low single-digit percentage range on Xetra. Trading volumes remain solid, supported by index inclusion and institutional interest, while options markets show a balance between hedging activity and yield strategies via covered calls. Observers note that the share price still sits well below the levels seen before the glyphosate litigation escalated, underscoring how legal uncertainties and shifting investor preferences have repriced the equity over recent years.

Where Bayer earns its money

Bayer generates revenue primarily from three segments: Pharmaceuticals, Consumer Health and Crop Science. The pharmaceuticals unit focuses on prescription medicines in cardiology, oncology and other specialty areas, while Crop Science offers seeds, crop protection and digital farming solutions, and Consumer Health sells over-the-counter products across multiple therapeutic categories.

Where the stock trades today

As of 2026-06-25, 12:45, Bayer shares trade on Xetra around 30.50 euros, reflecting recent sessions of relatively stable movement within a narrow range compared with broader DAX volatility.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.